Robust inflammation present in the HPV-active tumors, along with higher expression of immune checkpoint inhibitor targets TIGIT, CTLA4 and PDL-1 (Supplementary Table 2A), suggest that immune checkpoint inhibitor therapy may be a productive approach for these virally driven cancers. Here, TIGIT is linked to cancer.